Linkedin Youtube
Launch Digital Edition

Webinars and Commercial Conversations — Register Now

Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.

Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

Qiagen expands QIAstat-Dx syndromic testing menu

April 2022—Qiagen announced test enhancements to its QIAstat-Dx, a fully integrated molecular diagnostic testing solution with one-step sample processing that provides results in about one hour. The company is awaiting U.S. regulatory approval of a gastrointestinal panel designed to detect 22 common viral, bacterial, and parasitic pathogens that can cause potentially life-threatening infections. Qiagen has also registered for CE marking a meningitis/encephalitis panel designed to analyze 15 pathogens simultaneously and help distinguish between meningitis and encephalitis.

Opdivo + chemo approved as neoadjuvant treatment for NSCLC

April 2022—The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting. The treatment is approved regardless of PD-L1 status and is based on the CheckMate -816 trial, the first positive phase three trial of an immunotherapy-based combination used before surgery for resectable NSCLC.

Beckman Coulter Life Sciences, AmoyDx ink agreement

April 2022—Beckman Coulter Life Sciences has entered into an agreement with AmoyDx to develop applications on the Biomek NGenius liquid handling system. The Biomek NGenius system is scheduled to launch in the second quarter of this year; it is not intended or validated for use in diagnosis of disease or other conditions.

Roche launches Avenio Edge System

April 2022—Roche launched its Avenio Edge System, an all-in-one preanalytical platform that is designed to minimize manual touchpoints and includes ready-to-load reagents, validated protocols, onboard capabilities, and intuitive software to manage next-generation sequencing sample workflows.

Roche launches Cobas Pulse system

April 2022—Roche announced the launch of the Cobas Pulse system, the company’s newest generation of connected POC solutions for professional blood glucose management, in select countries accepting the CE mark.

Tribun Health gets KLAS award for digital pathology

April 2022—Tribun Health announced it won a 2022 “Best in KLAS” award for digital pathology in Europe. The Best in KLAS report from KLAS Research recognizes software and services companies that excel in helping health care professionals improve patient care.

Alcor, Water Street partner to accelerate expansion

April 2022—Alcor Scientific is partnering with Chicago-based health care investor Water Street Healthcare Partners. Water Street will invest in Alcor’s research and development initiatives, product portfolio, and international expansion. Alcor has appointed Jim Post as chief executive officer to lead its next phase of innovation and growth.

Qiagen expands QuantiFeron portfolio

March 2022—Qiagen announced expansion initiatives for its QuantiFeron portfolio, including developing new applications for technology designed to detect potentially deadly latent diseases. Among the company’s recent developments are the CE marking of its QuantiFeron SARS-CoV-2 assay, which launched in December 2021; the FDA’s expansion of the range of target groups that can be tested with the blood-based QuantiFeron-TB Gold assay, which now includes people with weakened immune systems, pregnant women, and children; and the Global Fund’s expert review panel for diagnostics’ approval of the QIAreach QuantiFeron-TB test, which means the test may now be procured by public health programs and institutions in more than 100 countries that qualify for Global Fund and Unitaid resources, as well as made available through the Stop TB Partnership’s Global Drug Facility.

Beckman, Illumina to develop applications for NGS system

March 2022—Beckman Coulter Life Sciences has signed an agreement with Illumina to develop applications on the Biomek NGeniuS Next Generation Library Preparation System, which is scheduled to launch during the second quarter of this year. The applications will be available to Biomek NGeniuS system users via a first-of-its-kind electronic application library, the company says.

Asuragen launches CFTR testing kit

March 2022—Asuragen has launched a kit to detect pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The AmplideX PCR/CE CFTR Kit, for research use only, is designed to detect about 93 percent of CFTR pathogenic variants observed in the U.S. population.

MARKETPLACE

TRENDING